NPTX2

Across TCGA pan-cancer cohorts, NPTX2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated NPTX2 data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher NPTX2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NPTX2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

THYM, LUAD, and KIRP are the cancer types where NPTX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LUAD	DFS	Median	II,III,IV	0.509	0.438	<.001	16	view →
KIRP	DFS	Median	II,III,IV	0.191	0.781	<.001	12	view →
READ	OS	Median	II,III,IV	0.527	0.933	.002	12	view →
UCEC	DFS	Median	All	1.000	0.631	.031	10	view →
GBM	DFS	Median	All	0.091	0.245	.049	3	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

NPTX2–THYM (OS)

Open the THYM breakdown →